Figure 1From: Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database Proportion of patients on each dose of RLAI over time (N = 784 at baseline). The proportion of patients on 12.5 mg was 0.5% at 1 month, 0.4% at 2, 6 and 7 months, 0.3% at 3 months, 0.2% at 4, 5 and 8 months. All other time points were 0%. RLAI, risperidone long-acting injection.Back to article page